#injectable

7 articles tagged #injectable.

Ready to compare providers? Take the 2-minute match quiz or see the cheapest GLP-1 options.

#2026 4 #503a 1 #503b 2 #alcohol 1 #alternatives 1 #ban 1 #before-and-after 1 #beginners 2 #berberine 1 #brand-name 3 #bridge-program 1 #cagrilintide 1 #cagrisema 1 #clinical-research 1 #clinical-trials 1 #comparison 2 #compounded 8 #compounded-glp1 1 #compounded-semaglutide 1 #compounded-tirzepatide 1 #compounding-ban 1 #copay 1 #cost 13 #coupon 1 #coverage 1 #diabetes 1 #diet 1 #dosage 1 #eli-lilly 3 #enforcement 1 #enrollment 1 #fact-check 2 #fda 4 #fda-approval 1 #flat-rate 1 #foundayo 7 #framework 1 #glp-1-patches 1 #glucose-monitors 1 #guide 1 #hhs 1 #hims 1 #how-to-get 1 #injectable 7 #injection 1 #insulin-resistance 1 #insurance 11 #ivy-rx 1 #ivyrx 1 #legality 1 #liraglutide 1 #medicaid 1 #medicare 5 #mounjaro 6 #natures-ozempic 1 #news 2 #novo-nordisk 2 #online-prescription 1 #oral-glp1 6 #oral-semaglutide 1 #orforglipron 4 #ozempic 9 #pcos 1 #personalized-treatment 1 #pill 1 #pipeline 1 #policy 1 #precision-medicine 1 #prior-authorization 2 #regulation 2 #results 1 #rfk 1 #ro 2 #safety 5 #savings-card 1 #schedule 1 #semaglutide 24 #serena-williams 1 #shortage 1 #side-effects 10 #storage 1 #supplements 2 #surmount 2 #surmount-5 1 #telehealth 1 #telehealth-enforcement 1 #telehealth-review 1 #timeline 1 #tirzepatide 22 #travel 1 #tsa 1 #type-2-diabetes 1 #wada 1 #warning-letters 1 #wegovy 17 #wegovy-hd 1 #wegovy-pill 3 #weight-loss 26 #weight-loss-plateau 1 #without-insurance 1 #zepbound 18

Editorial still-life illustrating retatrutide, a Phase 3 triple-agonist weight loss drug

Analysis News & PipelineAugust 5, 2026• 11 min read

Retatrutide TRIUMPH-1 Results (May 2026): 30.3% Weight Loss, Phase 3 Primary Trial

Updated August 5, 2026: Added Lilly's ClinicalTrials.gov expanded-access record (NCT07629401), registered June 5, 2026, which lists no eligibility criteria. Biologic classification lawsuit context (Lilly v. FDA, Case 1:24-cv-01503). Obesity (TRIUMPH-1): 28.3% weight loss at 80 weeks, 30.3% at 104 weeks, 65.3% achieved BMI <30. T2D (TRANSCEND-T2D-1): A1C −2.0%, weight −16.8%. NDA expected Q4 2026. Court ruling: FDA's bright-line classification of retatrutide as a drug (not biologic) vacated. Outcome determines whether compounding can legally exist post-approval.

Editorial still-life illustrating an Ozempic versus Wegovy semaglutide comparison

Analysis ComparisonsJuly 2, 2026• 18 min read

Ozempic vs Wegovy (2026): Same Drug, $1,028 vs $1,349 List, Here's Which You Need

Verified August 14, 2026: Ozempic and Wegovy are both semaglutide from Novo Nordisk. Ozempic ($1,027.51/mo list) is approved for type 2 diabetes at max 2mg. Wegovy ($1,349/mo list) is approved for weight loss at max 2.4mg (or 7.2mg HD). NovoCare lists each pen at $199/mo for the first two low-dose fills; Wegovy then costs $349/mo at standard strengths ($399 HD), while Ozempic costs $349/mo at 0.25-1mg or $499/mo at 2mg. Pills start at $149/mo and are dose-dependent.

Editorial still-life illustrating two parallel paths, a calm side-by-side comparison

Analysis ComparisonsJune 24, 2026• 11 min read

Mounjaro vs Ozempic (2026): The Honest Head-to-Head Your Doctor Won't Have Time For

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both FDA-approved only for type 2 diabetes, neither is approved for weight loss (that's their sister brands, Zepbound and Wegovy). In the first head-to-head trial, SURMOUNT-5, tirzepatide beat semaglutide for weight loss (−20.2% vs −13.7% over 72 weeks), and in SURPASS-2 tirzepatide cut A1C more. But Ozempic's semaglutide has the SELECT cardiovascular outcome data Mounjaro doesn't. Here's the data-driven breakdown, plus the cheaper cash-pay paths if your insurance says no.

Editorial still-life illustrating CagriSema, an investigational injectable weight loss drug from Novo Nordisk

Analysis News & PipelineJune 16, 2026• 9 min read

CagriSema 2026: Weight Loss Results, FDA Timeline & Why You Can't Buy It Yet

CagriSema (cagrilintide + semaglutide) lost 22.7% average body weight in adults with obesity (REDEFINE 1) and 13.7% in adults with type 2 diabetes (REDEFINE 2) over 68 weeks. Novo Nordisk filed its US application on December 18, 2025; an FDA decision is expected later in 2026 with no public PDUFA date. It is not FDA-approved and not legally available as of June 2026, here is the honest data, how it stacks up against drugs you can get today, and why every site selling 'CagriSema' right now is a red flag.

Editorial photograph illustrating the 2026 weight loss drug pipeline

Analysis News & PipelineMay 5, 2026• 13 min read

Next Weight Loss Drugs Pipeline (2026): Retatrutide 28.7%, CagriSema 22.7%, MariTide Monthly

Updated May 2026: 5 next-gen obesity drugs in Phase 3. Retatrutide (Lilly) 28.7% weight loss. CagriSema (Novo): REDEFINE-1 22.7% (obesity), REDEFINE-2 15.7% (T2D), PDUFA expected October 2026. MariTide (Amgen, monthly), survodutide, Foundayo approved April 2026. FDA approvals 2026-2028.

Analysis GuidesApril 11, 2026• 10 min read

Brand vs Compounded GLP-1 (2026): Wegovy From $199 vs Compounded Options

Verified August 7, 2026: NovoCare lists the brand-name Wegovy pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 for HD) and the oral pill from $149/mo, dose-dependent; Zepbound starts at $299/mo via LillyDirect. Compounded offerings may advertise lower prices but require product- and prescription-specific regulatory review.

Editorial photograph illustrating what to expect during the first month on a GLP-1 medication

Guide GuidesApril 11, 2026• 8 min read

First Month on GLP-1 (2026): 2-5 lbs Lost Week 1-4, Nausea Peaks Week 4, Week-by-Week

Verified July 2026: GLP-1 patients lose 2-5 pounds in their first month. Appetite suppression starts week 1-2. Nausea peaks at week 4 dose escalation. 98.1% of GI side effects are mild-to-moderate per STEP-1 and SURMOUNT-1 trials. Complete week-by-week timeline with dosing schedule.